Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.

The invention provides a composition for use as a medicament, comprising cells of a recombinant microorganism capable of producing increased amounts of one or more of 5-hydroxytryptophan (5-HTP), 5-hydroxytryptamine (5-HT) and tryptamine (TRM) as compared to the non-recombinant microorganism from which it was derived. The composition finds use in preventing and/or treating TRM-; 5-HTP-, or 5-HT-related disorders of the central nerve system (CNS); enteric nervous system (ENS); gastro intestine (GI) and metabolism in a mammal, and may be orally administered to a mammal in need thereof. Additionally, a composition comprising cells of a recombinant microorganism capable of producing melatonin is provided for use as a medicament, such as for treatment of depression, dementia, cancer and sleep disorder.

Described herein are variants of arylalkylamine N-acetyltransferase (AANAT) as well as vectors and recombinant microbial host cells expressing AANATs and variant AANATs and their use in producing N-acetylserotonin, melatonin and related compounds. Preferred AANAT variants provide for an increased yield of N-acetylserotonin.

Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.

Described herein are variants of arylalkylamine N-acetyltransferase (AANAT) as well as vectors and recombinant microbial host cells expressing AANATs and variant AANATs and their use in producing N-acetylserotonin, melatonin and related compounds. Preferred AANAT variants provide for an increased yield of N-acetylserotonin.

Provided herein are compositions and methods for stabilizing enzymes. Also provided are systems, compositions and methods for using the stabilized enzymes to produce a desired compound.

The present disclosure relate to a method for producing a tryptamine derivative of formula (I), wherein the tryptamine derivative (I) is not tryptophane, 4-hydroxytryptamine, N-acetyl-4-hydroxytryptamine, norbaeocystin, baeocystin; psilocybin, psilocin, aeruginascin, halogenated tryptophan, halogenated tryptamine, halogenated N-methylated tryptamine, halogenated N,N-dimethyltryptamine or halogenated N,N,N-trimethyltryptamine; said method comprising providing an indole acceptor of the formula (II), wherein the tryptamine derivative (I) is not tryptophane, 4-hydroxytryptamine, N-acetyl-4-hydroxytryptamine, norbaeocystin, baeocystin; psilocybin, psilocin, aeruginascin, halogenated tryptophan, halogenated tryptamine, halogenated N-methylated tryptamine, halogenated N,N-dimethyltryptamine or halogenated N,N,N-trimethyltryptamine; said method comprising providing an indole acceptor of the formula (II), wherein one or more of RII, RIV, RV, RVI or RVII is not H and Rill is H or CH2CH2NH2 or CH2CHCOOHNH2; and contacting the indole acceptor with a substituent donor in the presence of one or more enzymes substituting one or more H, OH and/or COOH in the indole acceptor with one or more substituents of the substituent donor.

##STR00001##